Method for correction of ischemic disorders caused by reperfusion liver injury. RU patent 2479872.
 Method for record of mechanical work of frog's isolated heart / 2479871Mechanical work of a frog's isolated heart is recorded by impedance cardiogram curve characterising contractive activity of the isolated heart in Ringer's solution for cold-blooded animals. The record is bipolar by means of "RheoSpectrum" rheographic system. In this case, one electrode is placed on a heart area to be examined, and the second one - into Ringer's solution surrounding the heart. |
 Training device for cervical therapeutic electrosurgical manipulations / 2479870Training device for cervical therapeutic surgical manipulations comprises a plastic holder for cervical model fixation. The holder is designed to comprise three seats. The seats are connected by an electric cable to a high-frequency electrosurgical instrument and designed to hold either cervical models, or rolled chicken. |
 Method for stimulating intestinal antiperistalsis / 2479869For the purpose of simulating intestinal antiperistalsis, a segment of the small intestine is isolated in a small laboratory animal. Serotonin adipate is introduced. 1% Serotonin adipate is introduced in a dose of 0.7-1.5 mg. Said dose is administered in two ways: a first portion of the dose is administered in the mesentery of a distal end of the isolated small intestine, and then the rest - in its wall. |
 Method for levelling optical density of extracted tooth dentin / 2478234Extracted tooth is placed in 10% nitric acid for 53 hours. Then it is placed in a disperse system of 96% alcohol and copper sulphate (II) for 50 hours. Then it is placed in a toluene solution for 20 hours. Then the prepared macropreparation is coated with Canadian fir resin 'Canadian Balm'. All the processes of exposition in the solutions are conducted in test tubes with tightly ground covers. |
 Method for endothelial dysfunction correction by solution of homoeopathic dilutions of tumour necrosis factor alpha antibodies / 2478233Endothelial dysfunction is induced in experimental Wistar male rats for 28 days by daily intraperitoneal introduction of N-nitro-L-arginine methyl ester (L-NAME) 12.5 mg/kg a day. An agent for dysfunction correction is a mixture of solutions of homoeopathic dilutions of tumour necrosis factor-alpha (TNF-α) antibodies - C12, C30, C200. This mixture is introduced at the same time for 28 day intragastrically 2 times a day in a dose of 4.5 ml/kg. |
|
Method for simulating intestinal dysbacteriosis in laboratory animals / 2477894 For the purpose of studying the variations of composition and properties of an intestinal microflora and explaining the approaches to disorder correction, the antibacterial preparation gentamycin is used to have an effect on the intestinal microflora of laboratory animals - white mice and porpoises. Viable microorganisms of the intestinal microflora are counted in the beginning and at the end of the test with the relevant numerical values to be compared. Gentamycin is administered per os 1 time a day for 5 days. A dose exceeding a daily therapeutic dose of gentamycin administered per os in 4.8 times in mice and 4 times in porpoises is used. |
|
Method for endothelial dysfunction correction by solution of homoeopathic dilutions of interleukin-6 antibodies / 2477530 Endothelial dysfunction is induced in experimental Wistar male rats for 28 days by daily intraperitoneal introduction of N-nitro-L-arginine methyl ester 12.5 mg/kg a day. An agent for dysfunction correction is a mixture of solutions of homoeopathic dilutions of interleukin-6 antibodies - C12, C30, C200; it is introduced at the same time for 28 day intragastrically 2 times a day in a dose of 4.5 ml/kg. |
|
Method for endothelial dysfunction correction by solution of homoeopathic dilutions of human endothelial nitrogen oxide synthase antibodies / 2477529 Endothelial dysfunction is induced in experimental Wistar male rats for 28 days by daily intraperitoneal introduction of N-nitro-L-arginine methyl ester (L-NAME) 12.5 mg/kg a day. The mixed solutions of homoeopathic dilutions of polyclonal rabbit human endothelial nitrogen oxide synthase antibodies C12, C30, C200 are used as an agent for dysfunction correction. This mixture is introduced at the same time for 28 day intragastrically 2 times a day in a dose of 4.5 ml/kg. |
 Method of treating malignant neoplasms in experiment / 2475865Method includes application of homeopathic preparation, obtained by double successive dilution with physiological solution to 1: 104 of heterologic liquor of patients with brain tumours after radical operation without development of recurrences at the moment of liquor obtaining. Said preparation is introduced to sexually mature non-pedigree rats with inoculated sarcoma 45, when tumours reach the dimensions 0.7-1.3 cm3, into subclavian vein in volume 0.3-0.4 ml depending on animal's weight. Introduction is performed 2 times within 2 weeks. |
|
Method of obtaining lung tumpours in experiment / 2475864 Suspension, containing 2 mg of 3,4-benzopyrene per 0.5 ml of 10% albumin solution and 0.5 of physiological solution, is introduced into subclavian vein of non-pedigree male rats. Suspension is obtained by ultrasonic processing, with frequency 44±4.4 kHz, with amplitude of fluctuations 30-50 mcm for 20 seconds. |
 Method of treating acute ischemic and hemorrhagic cerebrovascular disease / 2477637Invention refers to medicine and concerns methods of treating acute cerebrovascular disease. A method of treating acute ischemic and hemorrhagic cerebrovascular disease consists in administering a pharmaceutical composition containing a protein-polypeptide complex taken as a biologically active substance and prepared of fast-frozen embryo brain of hoofed farm animals of a gestation term from the middle of the first one-third to the middle of the last one-third of pregnancy, in the amount of 0.05-0.8 mg/day subcutaneously, intramuscularly, intravenously, intranasally and intrathecally. Said protein-polypeptide complex contains negative weak acid neutral proteins and polypeptides referring to growth/differentiation factors, signal molecules, intercellular adhesion molecule, of molecular weights 5 to 200 kD with min. 80% of total weight of proteins having molecular weight 10 to 120 kDa, and characterised nu a peak at UV wave length 274-284 nm and bands at the pi values of 4.2 to 8.4 at isoelectric focusing in 5% polyacrylamide gel. |
 Use of quartenary pyridinium compounds for vasoprotection and/or hepatoprotection / 2477132Invention refers to using a compound of formula (I): |
|
Method of early postoperative drug-induced correction of central hemodynamic disorders in oncological patients / 2477128 Invention refers to medicine, namely anaesthesiology, and concerns the early postoperative drug-induced correction of central hemodynamic disorders in oncological patients. That is ensured by measuring a cardiac index (CI), an impact index (II), a LV filling pressure (LVFP), a total peripheral vascular resistance (TPVR), a LV mechanical work index (LVMWI), a systolic blood pressure (SBP); the derived relations of these values in a patient are used to prescribe an individual drug-induced therapy. |
 Capsule and drug preparation for preventing cardiovascular diseases / 2477123Invention refers to pharmaceutical industry, particularly a drug preparation for preventing the development of cardiovascular diseases in individuals of a high-risk group. A capsule for preventing the development of cardiovascular diseases in individuals of a high-risk group which contains acetylsalicylic acid tablets coated by partially hydrolised polyvinyl alcohol (PVA), tablets of simvastatin and pravastatin coated by hydroxypropyl methylcellulose (HPMC) and tablets of lisinopril, ramipril or perindopril coated by partially hydrolised polyvinyl chloride. Using the capsule in producing the drug preparation for preventing the development of cardiovascular diseases in individuals of a high-risk group. |
 Novel tetrahydroisoquinoline derivative, pharmaceutical composition based thereon, use thereof and method of treating and/or preventing disease / 2474575Invention relates to novel tetrahydroisoquinoline derivatives of general formula (I) or pharmacologically acceptable salts thereof, where R1 is a phenyl aminocarbonyl group which can be substituted with 1-3 groups independently selected from a substituting group A, a heteroaryl aminocarbonyl group, where the heteroaryl is pyridine, pyrazine, thiazole, pyrazole or isoxazole, which can be substituted with 1 group selected from a substituting group A, benzoxazol-2-yl group, which can be substituted with 1 group selected from a substituting group A, benzothiazol-2-yl group, (C1-C6 alkyl which can be monosubstituted with a C3-C6 cycloalkyl group), aminocarbonyl group, (C3-C6 cycloalkyl)aminocarbonyl group or adamantyl aminocarbonyl group; R2 independently represents a C1-C6 alkyl group; R3 is a heterocyclic group, where the heterocycle is oxazole, oxadiazole, pyrazole, isoxazole or tetrazole, which can be substituted with 1 group selected from a substituting group A, a group of formula -C(=O)-O-R4, or a group of formula -C(=O)-N(R5)R6; R4 is a hydrogen atom, a C1-C6 alkyl group which can be substituted with 1-2 groups independently selected from a substituting group B; R5 is a hydrogen atom, a C1-C6 alkyl group which can be substituted with 1 group selected from a substituting group B, a C3-C6 cycloalkyl group which is monosubstituted with a carboxyl group, or a heterocyclic group, where the heterocycle is tetrazole, which can be substituted with 1 group selected from a substituting group A; R6 is a hydrogen atom or a C1-C6 alkyl group; in those cases when both R5 and R6 represent a C1-C6 alkyl group, which can be substituted with 1 group selected from a substituting group B, their carbon atoms can be bonded to each other to form a 5-member saturated ring; X is an oxygen atom, a methylene group, a group of formula -NH-, a methylene group which is monosubstituted with a C1-C6 alkyl group, or a group of formula -N(R7)-; R7 is a C1-C6 alkyl group; L is a single bond, a methylene group, a 1,1-dimethylmethylene group, an ethylene group, a group of formula - CH=, or a methylene group which is monosubstituted with a C1-C6 alkyl group; … denotes a single bond or a double bond (however, … denotes a single bond when L is a group of formula -CH=); m equals 1 or 2; n equals 0 or 1; substituting group A is a group of substitutes selected from a halogen atom, a C1-C6 alkyl group, a C1-C6 halogenated alkyl group, a C1-C6 alkoxy group, a C1-C6 halogenated alkoxy group, a C1-C6 alkylthio group, a carboxyl group, a di-(C1-C6 alkyl)amino group, a cyano group, a hydroxy group, a C1-C6 alkylthionyl group and an oxo group; and substituting group B is a group of substitutes selected from a carboxyl group and a hydroxy group. The invention also relates to a pharmaceutical composition based on the compound of formula (I), use of the compound of formula (I) and a method of treating and/or preventing a disease. |
 4-dimethyl aminobutyric acid derivatives / 2474573Disclosed are novel 4-dimethyl aminobutyric acid derivatives of formula (I) (pharmaceutically acceptable salts thereof), where values of A1, A2, R1, m and n are given in the claim, which inhibit activity of carnitine palmitoyltransferase (CPT), and more specifically CPT2. |
 Pyridinone pyridazinone derivatives as inhibitors of poly(adp-ribose) polymerase (parp) / 2472782Invention relates to compounds of formula (IX) wherein radicals and symbols have values given in the claim, and pharmaceutically acceptable salts or tautomers thereof. Said compounds are inhibitors of poly(ADP-ribose)polymerase (PARP) and can be used to treat cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV-induced skin damage, and as chemo- or radiosensitisers for cancer treatment. The invention also relates to a pharmaceutical composition containing said compounds, use of said compounds and a method of treating said diseases. |
|
Gel polysaccharide compositions and methods for prolonged drug delivery / 2472487 Invention refers to pharmaceutical industry and represents a biologically compatible polysaccharide gel composition possessing the properties of prolonged release and containing triamcinolone acetonide engrafted to hyaluronic acid by covalent binding of triamcinolone acetonide and hyaluronic acid. |
 Lyophilised dna compounds for increased plasmid dna expression / 2470995Invention refers to a lyophilised DNA compound to be applied for treating an ischemic disease and to a method of treating an ischemic disease in an individual. The lyophilised DNA compound contains plasmid DNA, salt and carbohydrate wherein said plasmid DNA contains HGF gene, or its version, and wherein said HGF gene, or its version is specified in a group consisting of flHGF, dHGF, NK1, NK2, NK4 or their mixture. The method of treating an ischemic disease in a human or a mammal involves the introduction of a composition recovered from the lyophilised DNA compound by direct injection. |
 Substituted 4-aryl-1,4-dihydro-1,6-naphthyridine amides and use thereof / 2470932Invention relates to novel substituted 4-aryl-1,4-dihydro-1,6-naphthyridine-3-carboxamides, method for production thereof, use thereof to produce a medicinal agent which inhibits MR activity. |
 Method of secondary prevention of hepatobiliary dysfunctions in children in conditions of increased contamination of biomedia with phenol, formaldehyde, methanol / 2478395Invention relates to medicine and is intended for prevention of hepatobiliary dysfunctions in children, living in conditions of contamination of atmospheric air with phenol, formaldehyde, methanol. Complex of medications ia applied. Eslidin in introduced perorally in 14-day course in age dosage from 3 to 7 years - 1 capsule 2 times per day, over 7 years - 1 capsule 3 times per day. Canephron N is introduced perorally, diluted in small amount of water, 2 times per day, to children of pre-school age in dose 10 drops, of school age - 20 drops per day with 10 day course; Flamin is introduced perorally 30 minutes before meal in dose 1-2 tablets per day with 10 day course; Jungle is introduced perorally during or after meal in dose 1 tablet 1 time per day with 21 day course; Immunal is introduced perorallyt 1 time per day with 10 day course in age dosage from 1 year to 6 years - 5-10 drops, from 6 to 12 years - 10-15 drops, over 12 years - in dose 20 drops. Course is repeated 1 time per year in children with light degree of disease course and 2 times per year in case of middle-severe disorders. |
FIELD: medicine.
SUBSTANCE: correction of ischemic disorders caused by reperfusion liver injury in experiment in white Wistar male rats involves modelling an ischemic and reperfusion liver injury. 30 Minutes before, L-norvalin arginase blocker 10 mg/kg is introduced intraperitoneally, and distant ischemic pre-conditioning is conducted. Then, another dose of L-norvalin arginase blocker is introduced immediately after liver ischemia.
EFFECT: effective correction of the hepatocellular damage ensured by minimising the oxidative stress effects.
1 tbl, 1 ex
The invention relates to medicine, in particular to the experimental , and can be used for the correction of ischemic and reperfusion damage to the liver in the experiment.
The closest one is a method of correction of hepatocellular damage by injection of N ω-hydroxy-nor-L-arginine with the dosage of 100 mg/kg 15 minutes prior to the insufficiency of the liver tissue and 15 minutes after the end of ischemia in the same dosage (M. Kaye Reid, Allan Tsung, Takahashi Kaizu, Geetha Jeyabalan, Atsushi Ikeda, Lifang Shao, Guoyao Wu, Noriko Murase and David A. Geller/Liver I/R injury is improved by the arginase inhibitor, N ω-hydroxy-nor-L-arginine // Am J Physiol Gastrointest Liver Physiol 292:512-517, 2007).
The main disadvantage of this method is that with N ω-hydroxy-nor-L-arginine cannot lead to significant reduction of hepatocellular damage. For elimination of this lack used the blocker arginase L- in a concentration of 10 mg/kg in combination with the distant ischemic .
The technical result of the invention is a method of correction of ischemic disorders resulting from reperfusion injury of the liver, including blocker arginase L- at a dose of 10 mg/kg in combination with the distant ischemic .
The technical result is achieved by the fact that in the experiment the 30 minutes prior to the simulation of reperfusion damage of the liver is their correction introduction blocker arginase L- at a dose of 10 mg/kg with the subsequent re-introduction of the same doses of the drug immediately after liver ischemia in combined with the distant ischemic , which leads to activation of the correction of ischemic reperfusion damage to the body.
The method is as follows.
Experiments are performed on male white rats Wistar weight 180-220, Latex turnstile is superimposed on the hepato-duodenum bunch of animals for 15 minutes. Remote preconditioning produce to the imposition of the turnstile. Blocker arginase L- injected intraperitoneally 30 minutes before the start of ischemia in a dose of 10 mg/kg, the same dosage of the drug is injected immediately after removal of the turnstile with cords. All manipulations are performed under General anesthesia: intra-abdominal introduction chloral hydrate in a dose of 300 mg/kg After 24 hours after the experiment under anesthesia (hydrate 300 mg/kg) produced blood of animals from the cavity of the heart for subsequent determination of serum transaminase levels. Studies performed on the automatic biochemical analyzer « E» (the Netherlands) with the use of reagents company «Biocon» and «Human» (Germany). Indicators ACT, ALT defined by the kinetic photometrically at 340 nm.
At the statistical processing of data was calculated average value, the standard deviation value. Differences was considered significant at p<0.05.
An example of a specific implementation.
Assessment of the degree of hepatocellular ischemic damage was performed on the basis of the difference in levels of serum transaminases animals. The level of ACT of animals undergoing ischemia/ liver, exceeded the intact group of 1.93 times respectively 100,0 U/l in intact and 193,0 U/l in animals after ischemia/reperfusion liver. ALT level in the animals undergoing ischemia/ liver, exceeded the intact group 3.2 times, respectively 62,1 U/l in intact and 196,8 U/l in animals after ischemia/reperfusion liver. In the group where the correction was made ischemic and reperfusion damage to the liver introduction of 10 mg/kg L- in conjunction with the distant ischemic , his transaminase were the following: ACT of 9.7±2,2 U/l; ALT - 3,0±to 0.4 U/l (table).
Indicators reflecting correction of hepatocellular damage on the background of a combination of remote ischemic preconditioning with the introduction of L- at a dose of 10 mg/kg
Groups of animals
Level ACT (IU/l)
The level of ALT (U/l)
Intact
100,0±1,8
62,1 ħ 3.8
Ischemia/reperfusion
193,0±27,1*
196,8±26,9*
Distant preconditioning + L- 10 mg/kg
9,7±2,2**
3,0±0/0,4**
Note: * - p<0.05 in comparison with intact, ** - p<0.05 in comparison with ischemia-reperfusion
Thus, the obtained results allow us to state the activation of correction of hepatocellular ischemic damage a combination of remote ischemic preconditioning with blocker arginase L- at a dose of 10 mg/kg
Method of correction of ischemic disorders arising from reperfusion injury of the liver, including modeling of ischemia/reperfusion of the liver, characterized in that experiment with white male rats Wistar model ischemic and reperfusion injury of the liver, 30 minutes before the intraperitoneally injected blocker arginase L- at a dose of 10 mg/kg and perform remote ischemic preconditioning, then re-enter the same dose of the antagonist arginase L- immediately after the insufficiency of the liver.